Ann Pediatr Endocrinol Metab.  2016 Jun;21(2):70-74. 10.6065/apem.2016.21.2.70.

Predictive factors for early response to methimazole in children and adolescents with Graves disease: a single-institute study between 1993 and 2013

• Hwang SM
• Kim MS
• Lee DY

• KMID: 2328144
• DOI: http://doi.org/10.6065/apem.2016.21.2.70

Abstract

PURPOSE
We aimed to investigate the predictive factors for early response to methimazole (MMI) in pediatric patients with Graves disease (GD).
METHODS
Our study included 44 pediatric patients who were diagnosed with GD between January 1, 1993, and December 31, 2013, and were available for follow-up, achieving a normalization of thyroid functions (TFs) at the Chonbuk National University Hospital Pediatric Department. We retrospectively analyzed TFs such as tri-iodothyronine (T3), free thyroxine (fT4), thyroid-stimulating hormone (TSH), and thyroid antibody levels at diagnosis. We also examined their family history of thyroid disease, symptoms at presentation, and normalization time for TF after treatment. We divided our clinical series of patients into the following 4 age groups: <7 years old, 7-12 years old, 13-15 years old, and 16-18 years old.
RESULTS
At diagnosis, the time of normalization of T3 was significantly shorter in the higher antimicrosomal antibody (AMA) group compared with the lower AMA group (2.53 months vs. 6.18 months) (P<0.05). However, the time of normalization of T3/fT4/TSH had no significant correlations with other variables such as age, sex, a family history of thyroid diseases, thyroglobulin, thyroid-stimulating immunoglobulin, or antithyroglobulin antibody (ATA).
CONCLUSION
Higher serological titers of AMA at diagnosis may have prognostic value in the response to initial MMI treatment in pediatric hyperthyroid GD patients.

Keyword

Graves disease; Triiodothyronine; Adolescent; Methimazole; thyroid microsomal antibodies

MeSH Terms

Adolescent*
Child*
Diagnosis
Follow-Up Studies
Graves Disease*
Humans
Immunoglobulins, Thyroid-Stimulating
Jeollabuk-do
Methimazole*
Retrospective Studies
Thyroglobulin
Thyroid Diseases
Thyroid Gland
Thyrotropin
Thyroxine
Triiodothyronine
Immunoglobulins, Thyroid-Stimulating
Methimazole
Thyroglobulin
Thyrotropin
Thyroxine
Triiodothyronine

Reference

1. Bettendorf M. Thyroid disorders in children from birth to adolescence. Eur J Nucl Med Mol Imaging. 2002; 29(Suppl 2):S439–S446. PMID: 12192543.

2. Sperling MA. Pediatric endocrinology. 2nd ed. Philadelphia: WB Saunders Co.;2002. p. 187–209.

3. Jaruratanasirikul S, Leethanaporn K, Sriplung H. Thyrotoxicosis in children: treatment and outcome. J Med Assoc Thai. 2006; 89:967–973. PMID: 16881428.

4. Abraham-Nordling M, Bystrom K, Törring O, Lantz M, Berg G, Calissendorff J, et al. Incidence of hyperthyroidism in Sweden. Eur J Endocrinol. 2011; 165:899–905. PMID: 21908653.

5. Metso S, Jaatinen P, Salmi J. Graves' disease. N Engl J Med. 2008; 359:1408–1409. PMID: 18822460.

6. Sperling MA. Pediatric endocrinology. 4th ed. Philadelphia: WB Saunders Co;2014. p. 12–453.

7. Krassas GE, Laron Z. A questionnaire survey concerning the most favourable treatment for Graves' disease in children and adolescents. Eur J Endocrinol. 2004; 151:155–156. PMID: 15248837.

8. Webster J, Taback SP, Sellers EA, Dean HJ. Graves' disease in children. CMAJ. 2003; 169:104–105. PMID: 12874154.

9. Gruneiro-Papendieck L, Chiesa A, Finkielstain G, Heinrich JJ. Pediatric Graves' disease: outcome and treatment. J Pediatr Endocrinol Metab. 2003; 16:1249–1255. PMID: 14714747.

10. Lippe BM, Landaw EM, Kaplan SA. Hyperthyroidism in children treated with long term medical therapy: twenty-five percent remission every two years. J Clin Endocrinol Metab. 1987; 64:1241–1245. PMID: 3571426.

11. Abraham P, Acharya S. Current and emerging treatment options for Graves' hyperthyroidism. Ther Clin Risk Manag. 2010; 6:29–40. PMID: 20169034.

12. Kliegman RM, Stanton B, St. Geme J, Schor N, Behrman RE. Nelson textbook of pediatrics. 19th ed. Philadelphia: Elsevier;2011.

13. Bahn Chair RS, Burch HB, Cooper DS, Garber JR, Greenlee MC, Klein I, et al. Hyperthyroidism and other causes of thyrotoxicosis: management guidelines of the American Thyroid Association and American Association of Clinical Endocrinologists. Thyroid. 2011; 21:593–646. PMID: 21510801.

14. Foley TP Jr. Thyrotoxicosis in childhood. Pediatr Ann. 1992; 21:43–46. 48–49. PMID: 1549398.

15. Zimmerman D, Lteif AN. Thyrotoxicosis in children. Endocrinol Metab Clin North Am. 1998; 27:109–126. PMID: 9534032.

16. Brook CG. Clinical paedriatric endocrinology. 3rd ed. London: Blackwell Science Ltd.;1995. p. 419–422.

17. Rivkees SA, Dinauer C. An optimal treatment for pediatric Graves' disease is radioiodine. J Clin Endocrinol Metab. 2007; 92:797–800. PMID: 17341574.

18. Lee JA, Grumbach MM, Clark OH. The optimal treatment for pediatric Graves' disease is surgery. J Clin Endocrinol Metab. 2007; 92:801–803. PMID: 17341575.

19. Cooper DS. Antithyroid drugs. N Engl J Med. 2005; 352:905–917. PMID: 15745981.

20. Allahabadia A, Daykin J, Holder RL, Sheppard MC, Gough SC, Franklyn JA. Age and gender predict the outcome of treatment for Graves' hyperthyroidism. J Clin Endocrinol Metab. 2000; 85:1038–1042. PMID: 10720036.

21. Benker G, Vitti P, Kahaly G, Raue F, Tegler L, Hirche H, et al. Response to methimazole in Graves' disease. The European Multicenter Study Group. Clin Endocrinol (Oxf). 1995; 43:257–263. PMID: 7586593.

22. Hamada N, Ito K, Mimura T, Ishikawa N, Momotani N, Noh J, et al. Retrospective reevaluation of the significance of thyroid microsomal antibody in the treatment of Graves' disease. Acta Endocrinol (Copenh). 1987; 114:328–335. PMID: 2436426.

23. Doniach D, Hudson RV, Roitt IM. Human auto-immune thyroiditis: clinical studies. Br Med J. 1960; 1:365–373. PMID: 13817519.

24. Kim HM, Yoon JY, Jung MH, Suh BK, Lee BC. Graves' disease in prepubertal children compared with pubertal children. J Korean Pediatr Soc. 2003; 46:76–82.

25. Song SM, Youn JS, Ko JM, Cheon CK, Choi JH, Yoo HW. The natural history and prognostic factors of Graves' disease in Korean children and adolescents. Korean J Pediatr. 2010; 53:585–591.

26. Lee SH, Lee SY, Chung HR, Kim JH, Kim JH, Lee YA, et al. Remission rate and remission predictors of Graves disease in children and adolescents. Korean J Pediatr. 2009; 52:1021–1028.